Kyowa Hakko Kirin, Orexo's partner, has filed a new drug application (NDA) seeking Japanese approval for KW-2246 as cancer pain medication. The sublingual formulation of fentanyl earlier gained approval in US, EU and Canada as cancer ...
Tags: new drug application, cancer pain medication, pharmaceutical product